PCN138 - Cost-Effectiveness Analysis of Regorafenib for Third-Line Metastatic Colorectal Cancer (MCRC) Compared to Cetuximab Plus Irinotecan in China
- Resource Type
- Abstract
- Source
- In
Value in Health May 2018 21 Supplement 1:S33-S33 - Subject
- Language
- ISSN
- 1098-3015